Pioneer Pharma revenue drops, profit halves despite strategic investments

Shanghai Pioneer Holding Ltd. reported a 20.9% decrease in revenue to RMB647.3m for the six months ended June 30, 2025, down from RMB818.0m in the previous year. Net profit also fell by 48.1% to RMB45.8m. The decline was primarily attributed to a substantial decrease in government grants and lower sales across its pharmaceutical products and medical devices segments, including a 58.0% drop in revenue from products sold via channel management services.

Despite the financial downturn, the company's total bank borrowings increased to RMB133.2m, with new long-term borrowings of RMB89.0m for construction projects at its Rongchang Production Base. This strategic initiative, which commenced operations in August 2025, aims to transform the company into a comprehensive pharmaceutical entity integrating R&D, production, and sales. The company also declared an interim dividend of HK$0.064 per share.

Shanghai Pioneer continues to pursue investments, with RMB28.5m in Shanghai Yuhan Fund and RMB12.2m in Jiaxing Yuhan Fund, specializing in pharmaceutical industry targets. The register of members will close from September 15-18, 2025, with dividend payments scheduled for October 20, 2025.